@FlySWISS Rocking that swindling look @FlySwiss where are you spending customers money and double booking and not refunding. Enjoy the slopes, and #flyanyonebutswiss
In its 22nd year, the UN @globalcompact launched successful strategies & programmes that helped spread its message and encourage companies to sign on and align their priorities towards #sustainability.
Check out these 2022 highlights:
https://t.co/kfYZ4qtGOM
#UnitingBusiness
“Together, let's continue #UnitingBusiness for a better world!” – a holiday message from Assistant Secretary-General @SandaOjiambo, Executive Director & CEO of the UN @globalcompact: https://t.co/LZ9LQ3qGCz
➡️ The #GFINDER data portal provides open access to all underlying data captured in our 2020 sexual and reproductive health R&D report. #UNGA#SRSH#StandUp4HumanRights Check it out: https://t.co/QtQCpTdGsD
Thanks @RobinBisson for the great article in @ResearchProfes on our new #GFINDER on emerging infectious diseases and preventing the next #pandemic
Infectious disease funding ‘follows the headlines’ https://t.co/AHg0Id6UP0
Curious how much governments and industry are spending on R&D to meet the 🌎’s needs to fight emerging infectious diseases that could cause the next #pandemic? 📉 📈Analyse funding trends over time on the #GFINDER data portal: https://t.co/QtQCpTdGsD
Curious how much governments and industry are spending on R&D to meet the 🌎’s needs to fight emerging infectious diseases that could cause the next #pandemic? 📉 📈Analyse funding trends over time on the #GFINDER data portal: https://t.co/QtQCpTdGsD
More than half of all emerging infectious disease R&D funding between 2014 and 2018 went to #vaccine research 💉, but only 18% to #treatments 💊and less than 4% to #diagnostics 🔬, says new #GFINDER https://t.co/48d7o0oR5U
Lassa fever R&D funding grew to $45m in 2018 says new 2020 #GFINDER EID report, largely due to increased funding by @CEPIvaccines https://t.co/48d7o0oR5U
The 2020 #GFINDER EID R&D report shows funding to fight #COVID19's cousins, SARS and MERS,was only $41m in 2018 - before the #pandemic hit, but this R&D jumpstarted the #COVID-19 R&D process https://t.co/48d7o0oR5U
Great article by @carmenpaun in @politico that cites our #COVID19 R&D tracker and quotes our CEO Dr Nick Chapman:
Still wanted: a treatment for the coronavirus https://t.co/wUGRtCy2wn
Prepared for the next pandemic? Let’s hope so. It starts with R&D. We’re launching our new #GFINDER on the R&D funding landscape for emerging infectious diseases like #Ebola#Zika and more https://t.co/ZLdEjsFnhU
We’re closer than ever to developing the next generation of SRH tools and treatments to meet EVERYONE’s needs - but we aren’t there yet. Check out the latest #GFINDER report to learn more about how SRH R&D is paving the way to the future: https://t.co/48d7o0oR5U
In 2018, $1.7 billion went to reimagining today’s technologies & researching next-generation tools to meet the sexual and reproductive health needs around the 🌎. Learn more: https://t.co/48d7o07fHk #GFINDER
NEW FINDINGS: #GFINDER report breaks down the latest data on R&D investments in sexual and reproductive health 📈 . Follow the 💰 to gain new insight on progress against the issues burdening millions today. https://t.co/48d7o0oR5U
Great piece by @carmenpaun in @politico on how
"Europe has yet to live up to its #COVID promises," that cites our #COVID R&D tracker showing at least 938 products in the pipeline to fight COVID amongst other great sources noted https://t.co/DOrXuXdmqB